This company presentation provides an overview of a cancer genetic testing services company. Key points include:
- The company has experienced strong and consistent growth in revenue and test volume over the past 10 years through both organic growth and acquisitions.
- It provides a broad menu of genetic and molecular testing services including next generation sequencing and is developing liquid biopsy tests.
- The company has an experienced management team with experience in large reference laboratories. It is focused on innovation, cost management, and expanding its commercial footprint.
- Financial results show increasing margins, productivity, and adjusted EBITDA despite lower average prices per test, demonstrating strong operating leverage as the business scales.
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast...Hawk Associates, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast...Hawk Associates, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
NeoGenomics is a fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals. This is August 2014 Company Overview Presentation.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Circulating Tumor Cell, Cell Free DNA, Exosome and Vesicle Cancer Diagnostic ...MarketResearch.com
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
Company Overview Presentation for November 2014.
-Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community.
-Offer the complete spectrum of diagnostic services in FISH, Flow Cytometry, Cytogenetics, digital pathology, immunohistochemistry, and molecular testing through nationwide network of laboratories
-Dedicated to providing superior service, faster TAT, and complete attention to the needs of our clients and their patients
NeoGenomics is a fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals. This is August 2014 Company Overview Presentation.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Circulating Tumor Cell, Cell Free DNA, Exosome and Vesicle Cancer Diagnostic ...MarketResearch.com
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
Company Overview Presentation for November 2014.
-Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community.
-Offer the complete spectrum of diagnostic services in FISH, Flow Cytometry, Cytogenetics, digital pathology, immunohistochemistry, and molecular testing through nationwide network of laboratories
-Dedicated to providing superior service, faster TAT, and complete attention to the needs of our clients and their patients
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
The intensifying global focus on oncology reflects its increasing impact on patients and expanding share of healthcare expenditure. Relative to other parts of the healthcare system, oncology brings high levels of uncertainty—in terms of the nature and rate of innovative treatments, the willingness by payers to reimburse care at current levels, and the shifting composition of the cancer patient population from mature and developed markets to low- and middle-income countries. As the sales of cancer treatments rise to $100 billion annually, more intensive scrutiny of this market can be expected and a deeper understanding of global oncology trends will be required by all stakeholders.
1390 Identification Of Prognostic Factors Using Quantitative Image Analysis O...Daniel Nicolson
Schmidt G, Binnig G, Feuchtinger A, Walch A : Identification of Prognostic Factors using Quantitative Image Analysis of HER2 Expression by Immunohistochemistry (IHC) in Adenocarcinoma of the Esophagogastric Junction Background: Since adenocarcinoma of the oesophagogastric junction is known to show human epidermal growth factor receptor 2 (HER2) overexpression we investigated the potential of IHC stained cancer tissue to provide information about disease free (DFS) and overall survival (OS) times. We compare the prognostic value of a visually assessed scoring algorithm derived from Dako HercepTestTM with results provided by data mining information from quantitative image analysis. Methods: Three tissue microarrays (TMAs) comprising 391 cores from tissue samples of 150 patients were analysed. After IHC staining with HER2 antibody the TMAs were scanned with Zeiss MIRAX slide scanner (20x objective). Fully automated image analysis using the Definiens Cognition Network Technology® segmented and classified cells, nuclei, cytoplasm and membrane objects, and determined on a per cell basis shape, texture and color properties. Those were correlated with known DFS/OS times using a multivariate regression analysis within the R statistical software. Based on this predictive model, the patient population was divided in one group with good and one with poor prognosis by imposing a threshold on the predicted survival times. The corresponding groups obtained by the pathologist scoring were HER2 score 0, 1+, 2+ versus HER2 score 3+. Result: Kaplan-Meier Analysis revealed a significant (DFS: p < 2.4x10-6; OS: p < 2.5x10-7) prognostic value for the two groups generated by data mining image analysis results, whereas the visually assessed score was not significant (p>0.1). Conclusion: Data mining quantitative image analysis may provide a more accurate evaluation of HER2 evaluation than a visual assessment of tissue samples. The quantification of HER2 overexpression by image analysis may be also highly valuable for the prediction of anti-HER2 therapy in combating this cancer type. (Presentation given at the 52nd Symposium of the Society for Histochemistry, Prague, Sept 1 - 4)
To purchase the full report follow this link https://goo.gl/kKrtGt
Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025. PharmaVitae casts its eye out to 2025 as crystallizing trends in healthcare management will influence Big Pharma to further position itself towards providing value. Big Pharma will add $39bn in revenues out to 2025, generating $464bn in prescription pharmaceuticals at a low single-digit compound annual growth rate of 0.9%. A healthy launch portfolio will bolster growth as Big Pharma reaps the reward of breakthrough products as the result of recent industry innovation. However, the low single-digit CAGR is representative of the overall drag that Big Pharma is facing. Three themes will shape the outlook: evolving business models, market access, and productivity.
Key questions answered
Revenue analysis
Which will be the best performing companies out to 2025?
Which companies will propel revenue growth over the forecast period?
How will Big Pharma perform across the US, 5EU, Japan and RoW regions?
Which companies will have leading market share gains and market share losses?
Therapy area analysis
How are late-stage pipelines positioned and what are the most-coveted launch products?
How many new blockbuster positions will Big Pharma carve out to 2025?
Which therapy areas will experience the largest growth and decline?
Where are companies building leadership positions in specific therapy areas?
What are the detailed competitive dynamics at play in the oncology, metabolic and, infectious diseases markets?
Strategy analysis
Will there be drastic shifts in the proportion of prescription drug revenue that is attributed to R&D?
How is Big Pharma using M&A to propel strategic goals?
What is the current status of biosimilar filings and how will they affect the performance of Big Pharma?
What strategies have been key for the commercial success of products launched in the past few years?
Highlights
Big Pharma prescription drug sales are forecast to grow to $464bn by 2025 at a compound annual growth rate of 0.9%
Number one company in 2025: Pfizer sustains top ranking in prescription drug sales out to 2025
Most valuable product: Humira will continue to be the highest selling product in 2025 with global sales forecast at $11bn
Most lucrative therapy area: Oncology will supplant metabolic in 2023 to become the most valuable therapy for Big Pharma
Most valuable class: PD-1/PD-L1 inhibitors will continue to build momentum out to 2025
Pipeline launch analysis: Big Pharma’s launch portfolio is set to add $134bn in revenues out to 2025
Most valuable company pipeline: Gilead will add pipeline revenues of $19bn out to 2025.
To purchase the full report follow this link https://goo.gl/kKrtGt
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
NeoGenomics Company Overview 07/24/2014. An emerging leader in fastest-growing segment of lab testing industry. They hold a robust competitive advantages and product portfolio. They have a strong management team with outstanding industry experience.
Company Overview Presentation for NeoGenomics:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics Company Overview presents investment highlights. It provides details on its growing cancer genetics lab servicing oncologists, pathologists and hospitals, its strategic client partnerships, its dynamic, rapidly-growing and consolidating industry and much more…
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.
In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics Forward-looking statements, Investment Highlights, Consistent Historical Growth, Accelerating Cash FLow & Earnings, Management Team, Cancer Testing Services, Customer Targets, NeoGenomics Formula for Success, Industry Dynamics, US Cancer Testing Market Size, Cancer Testing Market Characteristics, Key Growth Drivers Over the Next 3 Years...
NeoGenomics Company Overview highlights. It includes investment highlights, Consistent historical growth charts, accelerating cash flow & earnings, management team, testing services, customer targets, formula for success, industry dynamics, U.S. cancer market size, cancer testing market characteristics, key growth drivers...
NeoGenomics overview presetnation ontains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after
Similar to NeoGenomics Company Overview 03/16/2015 (16)
COVID-19 PCR tests remain a critical component of safe and responsible travel in 2024. They ensure compliance with international travel regulations, help detect and control the spread of new variants, protect vulnerable populations, and provide peace of mind. As we continue to navigate the complexities of global travel during the pandemic, PCR testing stands as a key measure to keep everyone safe and healthy. Whether you are planning a business trip, a family vacation, or an international adventure, incorporating PCR testing into your travel plans is a prudent and necessary step. Visit us at https://www.globaltravelclinics.com/
Under Pressure : Kenneth Kruk's StrategyKenneth Kruk
Kenneth Kruk's story of transforming challenges into opportunities by leading successful medical record transitions and bridging scientific knowledge gaps during COVID-19.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...rowala30
Alka magic plan 1350 -we deliver alkaline water at your door step and you can make handsome money by referral programme
we also help and provide systematic guideline to setup 1000 lph alkaline water plant
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...The Lifesciences Magazine
Cold Sores, medically known as herpes labialis, are caused by the herpes simplex virus (HSV). HSV-1 is primarily responsible for cold sores, although HSV-2 can also contribute in some cases.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
NeoGenomics Company Overview 03/16/2015
1. Company Overview Presentation
March 2015
“Improving Patient Care
through exceptional cancer
genetic testing services!”
Time Matters. Results Count!
2. Forward-looking Statements
This presentation contains statements which constitute forward-looking statements within the meaning
of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934;
and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”,
“expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and
variations thereof are intended to specifically identify forward-looking statements. All statements that
are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and uncertainties, and that actual results may differ
materially from those projected in the forward-looking statements as a result of various factors. The
risks that might cause such differences are identified in our filings with the Securities and Exchange
Commission. We undertake no obligation to publicly update or revise the forward looking statements
made in this presentation to reflect events or circumstances after the date of this presentation or to
reflect the occurrence of unanticipated events.
2
3. Investment Highlights
Fast growing cancer
genetics lab servicing
Oncologists,
Pathologists and
Hospitals
Strategic client
partnerships created
by “Tech-Only” model
Dynamic, rapidly-
growing and
consolidating industry
Industry-leading
revenue & test volume
growth
Strong productivity and
operating leverage
leading to accelerating
cash flow and net income
Strong Management
Team with large cap
lab experience
3
4. Experienced Management Team
• Douglas VanOort, Chairman & CEO
Chief Operating Officer, Quest Diagnostics
Executive Vice President, Corning Life Sciences, Inc.
• Maher Albitar, M.D., Chief Medical Officer & Director of R&D
Med. Dir. for Hematopathology & Oncology and Chief of R&D, Quest Nichols Institute;
Director of Leukemia and Molecular Laboratory, MD Anderson Cancer Center
• Robert Shovlin, Chief Operating Officer
Chief Development Officer, Bostwick Laboratories
President & Chief Executive Officer, Aureon Biosciences
• Steven Jones, Director, EVP – Finance, & Chief Compliance Officer
Chairman, Aspen Capital Group; Managing Member, Medical Venture Partners
Vice President, Merrill Lynch Investment Banking
• George Cardoza, Chief Financial Officer
CFO, Protocol Global Solutions; Controller, Central Region, Quest Diagnostics
• Robert Horel, Vice President & General Manager, PathLogic
Regional Mgr., US Labs; Product Specialist, Ventana Medical Systems; Pilot, U.S. Navy
• Steven Ross, Chief Information Officer
Vice President Technology, Chico’s FAS, Inc.
4
5. Company Overview
• Specialized oncology reference laboratory providing
the latest testing technologies, global/tech-only
options, and interactive education to the pathology
community
• Offer the complete spectrum of diagnostic services
through nationwide network of laboratories
• Dedicated to providing superior service, faster turn-
around times, and complete attention to the needs
of our clients and their patients
• Founded and went public in 2001
• First to launch tech-only FISH services in 2006
• March 2009, Doug VanOort joined as CEO
• December 2012, up-listed to NASDAQ
• Recently completed acquisition of Path Logic based in
West Sacramento, California
• 65% CAGR in Revenue and Test Volume over last ten
Years.
Description Broad Menu of Genetic & Molecular Tests
History
5
• 57 Custom FISH Panels
• 215 IHC Stains and Custom Panels
• 72 Molecular Markers
• 23 Targeted NeoTYPE Molecular/FISH/IHC Panels
• Full Suite of Next Generation Sequencing Panels
315 Gene Solid Tumor Discovery Panel
4,813 Gene Cancer Exome Profile
• Cytogenetics
• Flow Cytometry
7. U.S. Cancer Testing Market Size $10-12 Billion
Hematopoietic Cancers Solid Tumor Cancers
Total Testing Market: $3 - 4 Billion $7 - 8 Billion
Est. Genetic Mkt. (TAM)
~$2 - 3 Billion ~$2 - 3 Billion
Patients in Treatment: 850,000 7.0 million
New Diagnoses/Yr.: 150,000 1.45 million
Specimen Types:
Bone Marrow (350K/Yr)
Per. Blood (150K/Yr)
Lymph Nodes
Tiss. Biopsies (8-10MM)
Fine Needle Aspirates
Other Bodily Fluids
Neo Revenue Split: ~80% ~20%
7
8. NeoGenomics’ Cancer Testing Services
Key Testing Methodologies
• Cytogenetics: chromosome analysis
− “Neighborhood view of 46 houses from 1000 feet”
• Flow Cytometry & IHC: cell surface marker analysis
− “Single house view from 500 feet”
• Fluorescence in-situ Hybridization (FISH): gene analysis
− “Door and window view of one house”
• Molecular Testing: DNA/RNA analysis
− “View of serial number on door lock”
8
9. Customer Targets
Pathologists & Hospital Pathology Groups (about 75% of 2014 Revenue )
• Enable community Pathologists to practice using sophisticated tools and tests
• Innovative technical component (TC or “tech-only”) services – Flow, FISH, IHC
• Outstanding Web-based Lab System & extensive training programs
Oncologists & Clinician Groups (about 22% of 2014 Revenue )
• Includes Hematologists, Oncologists, Dermatologists, Urologists
• Disease Panels and comprehensive molecular menus
• Increasing Opportunity to service larger practices with Tech-only model
Clinical Trials & Other (about 3% of 2014 Revenue )
• Contract research/clinical trial support work for Pharma clients
9
10. Accelerating Pace of Innovation
• 4 molecular tests
• 3 FISH
• FL – IHC menu
• 10-color Flow Cytometry
• Implemented State-of-the-art
MolDx platform in lieu of Kits
• 28 new Molecular Assays
• Proprietary method for
increasing sensitivity of
Sanger sequencing
• 7 NeoTYPE MolDx Panels
• New Aperio Digital Image
Analysis
• SVM for FISH (Patent App)
• Barrett’s Esoph. FISH
(Patent App)
• NeoARRAY/SNP
Cytogenetics
• Internalized send-outs
• 40 new Molecular tests
• Add’l NeoTYPE Panels
• Next Generation
Sequencing (48 genes)
• ROS1 FISH
• NeoSITE Melanoma FISH
• Plasma/Urine-based
Prostate Test (Patent
App)
• SVM-based Cytogenetics
Analysis System
• SVM-based Automated
FISH Analysis System v2
• Began development of
NeoLAB (Liquid
Alternative to Biopsy)
Prostate Cx test
2011
2012
2013
10
• 60 new/rev’d Molecular tests
• 24 new NeoTYPE Next
Generation Sequencing
Profiles
• 26 new IHC/ISH tests
• Additional NeoLAB Prostate
clinical studies
• AML Extended FISH Panel
• AML Favorable-Risk FISH
Panel
• MDS Extended FISH Panel
• Plasma Cell Myeloma Risk
Stratification FISH Panel
• RET FISH
• MET FISH
• ALL Adult & Pediatric FISH
Panels
• HER2 Breast Equivocal
FISH Panel
• BRAF Translocation FISH
• Chromosome 1 POC Ploidy
• Launched robotic FISH/Cyto
pre-processing platform
2014
11. Next Generation Sequencing and Liquid Biopsies
Next Generation Sequencing
• 21 tumor-specific hematologic and solid tumor profiles
• 4 broad pan-tumor profiles (54 gene Myeloid Disorders Profile, 48 gene Precision
Profile for Solid Tumors, 315+ gene Discovery Profile for Solid Tumors, Cancer Exome
Profile
• Tech-only FISH/Flow option available for select NeoTYPE Profiles
• Comprehensive and clear reporting of key diagnostic, prognostic, therapeutic and
clinical trials information relevant for informed decision making
NeoLAB (Liquid Alternative to Biopsy) Prostate Text
• Blood Plasma & Urine-based (no need for Prostate tissue)
• Designed to inform which patients with elevated PSA should be biopsied
• Pivotal validation study underway (800 - 1,000 patients)
• Commercial launch expected in 2H 2015
• Expected pricing $400 - $600/Test
11
12. A Growing Commercial & Facility Footprint
NV
OR
WA
MT
MN
NE
ND
ID
WY
OK
KS
COUT
TX
NM
SC
FL
GAALMS
LA
AR
MO
IA
VA
NC
IN
KY
IL
MI
WI
PA
WV
VT
RI
NH
AZ
OH
DE
MD
NY
CA
NJ
MI
MA
SD
States sending specimens in 2014
ME
CT
Irvine, CA
25k sf
Nashville, TN
7k sf
Ft. Myers, FL
45k sf
Tampa, FL
5k sf
W. Sacramento,
CA
17k sf
Fresno, CA
3k sf
12
SD
13. Large & Growing Clinical Trials Opportunity
• World class Molecular Oncology menu opening up numerous opportunities to
directly service pharmaceutical companies.
− Leverages NEO Pathologist expertise, Lab systems, Tech-only model, comprehensive
menus to further diversify into a new segment.
− Ability to expand into world-wide markets
− Potential for developing companion diagnostics
− Access to market with higher AUP
• Exclusive 5 year Agreement with Covance, with a two year renewal option.
− NEO exclusively provides professional interpretations for all AP and Histology testing
ordered with new trials worldwide
− NEO exclusively provides all technical component FISH for samples tested in the U.S.
− NEO eligible to provide technical component services for all U.S. based testing that is
not otherwise performed by Covance’s Lab-within-a-Lab (LWL) facility at NEO
13
14. $10
• On July 8, 2014, NEO announced and closed the
acquisition of Path Labs, LLC dba “Path Logic” for $6
million
2013 Revenue of $9.8 million
Implied Enterprise Value/Revenue of 0.6x
Includes $150,000 in capital lease obligations
$5.85 million at closing paid with cash on hand and
borrowings from its revolving credit facility with and
$.60 million held in escrow
• Path Logic will operate as a wholly-owned subsidiary of
NeoGenomics
Acquisition of Path Logic
Strategic RationalePath Logic Overview
Transaction Summary
• A specialized AP laboratory serving California and the
western United States
• Sub-specialties in renal pathology, dermatopathology,
women’s health and gastrointestinal and genitourinary
pathology
• Approximately 65 employees as of July 2014, including
9 in-house pathologists and 12 consulting pathologists
• Founded in 1999 and headquartered in West
Sacramento, California
• NEO expects $3 – 4 million of revenue synergies
by offering NEO tests to Path Logic customers and
Path Logic tests to NEO customers
• Additional cost synergies with increased run rate
and NeoGenomics experience
• Doubles pathology staff
• Expansion of geographic footprint in Northern
California with West Sacramento, California
laboratory
- Location to be added to NeoGenomics
- Locations to be discontinued
14
15. 2015 Strategic Priorities
• Next Gen Sequencing
• Develop Prostate Cancer Test
• Launch New Products
• Grow Clinical Trials
• Optimize Covance partnership
• Higher Productivity
• Lower Costs
• Become a “Digital Lab”
• Expand Sales Team
• Add new clients
• Improve Informatics
Growth Get LEAN
InnovateDiversify
15
17. Increasing Margins Despite Lower Avg Unit Prices – Base NEO*
* For comparison purposes Base NEO exclude the impacts from the Path Logic Acquisition, which was completed on 7/8/14.
(1) Productivity calculated as the average number of lab tests completed per month per laboratory FTE.
17
47.3%
48.4%46.1%
44.7%44.6%43.9%44.5%44.8% 45.2%
47.1%
47.2%
41.5%
43.2%
46.3% 45.9%48.4%
50.0%
47.9%
49.5%
46.4%
48.2%
-23.7%
58.6%
-40%
-20%
0%
20%
40%
60%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100% Q409
Q110
Q210
Q310
Q410
Q111
Q211
Q311
Q411
Q112
Q212
Q312
Q412
Q113
Q213
Q313
Q413
Q114
Q214
Q314
Q414
Gross Margin % Cum Change in Avg Rev/Test Cum Change in Productivity(1)
18. Operating Cost per Test & Adj. EBITDA Margin
Cost Management & Operating Leverage – Base NEO*
18
$723
$642$642
$671
$649
$618
$576$565
$555
$531$512 $526
$482$478
$464 $466$439
$459
$442$457
$431
-12%
-1%
-2%
-5%
0%
-1%
5%
6%
8%
12%
12%
6%
10%11% 12%
13%
15%
9%
10%
14%
14%
-15%
-10%
-5%
0%
5%
10%
15%
20%
$0
$100
$200
$300
$400
$500
$600
$700
$800
Q409
Q110
Q210
Q310
Q410
Q111
Q211
Q311
Q411
Q112
Q212
Q312
Q412
Q113
Q213
Q313
Q413
Q114
Q214
Q314
Q414
Cogs Cost/Test G&A Net of R&D Cost/Test
S&M Cost/Test R&D Cost/Test
* For comparison purposes Base NEO exclude the impacts from the Path Logic Acquisition, which was completed on 7/8/14.
19. Quarterly Financial Information (P&L)
($, 000's) Q4 13 Q1 14 Q2 14
Base NEO
Q3 14(1)(2)
Base NEO
Q4 14(1)
Consolid.
Q4 14(3)
Total Revenue $18,323 $ 18,182 $ 20,670 $ 20,835 $ 22,505 $ 24,998
% Growth (YoY) 23.0% 16.1% 32.5% 23.4% 22.8% 36.4%
Total Gross Profit 9,163 8,710 10,240 9,664 10,842 11,470
Gross Margin % 50.0% 47.9% 49.5% 46.4% 48.2% 45.9%
Total SG&A (Incl R&D) Exp 7,959 8,316 9,661 9,369 9,064 10,152
SG&A as a % of Rev 43.4% 45.7% 46.7% 45.0% 40.3% 40.6%
Net Income/(Loss) $ 858 $ 102 $ 274 $ 23 $ 1,507 $ 1,047
Diluted EPS $0.02 $0.00 $0.01 NA NA $0.02
Adjusted EBITDA $ 2,733 $ 1,685 $ 2,114 $ 2,862 $ 3,174 $ 2,637
Operating Data – Base NEO
% Growth in Tests (YoY) 27.8% 20.7% 39.8% 33.4% 23.4%
Avg. Revenue/Test $ 470 $ 469 $ 455 $ 463 $ 468
% Change (YoY) -3.7% -3.8% -5.3% -7.5% -0.4%
Avg. COGS/Test $ 235 $ 245 $ 229 $ 248 $ 243
% Change (YoY) -15.3% -6.7% -11.7% -3.9% 3.2%
(1) For comparison purposes Q3 & Q4 Base NEO exclude the impacts from the Path Logic Acquisition, which was completed on 7/8/14.
(2) Q3 SG&A includes $571,000 of one-time transaction expenses related to the PathLogic acquisition and the termination of the Company’s Credit Facility.
(3) Q4 Consolidated Financials Include Path Logic.
19
20. Consolidated Balance Sheet
($, 000's)
12/31/13 9/30/14 (1)(2) 12/31/14
ASSETS:
Cash & Cash Equivalents $ 4,834 $ 34,366 $ 33,689
Other Current Assets 22,657 22,877 24,820
Prop and Equip, Net 9,694 14,636 15,082
Other LT Assets 2,731 6,940 7,281
Total Assets $ 39,916 $ 78,820 $ 80,873
LIABILITIES & STOCK HOLDERS’ EQUITY:
Current Liabilities $ 14,323 $ 13,954 $ 14,623
Long-Term Liabilities 3,882 5,801 5,845
Total Liabilities 18,204 19,755 20,468
Stockholders’ Equity 21,711 59,065 60,405
Total Liabilities and Stockholders’ Equity $ 39,916 $ 78,820 $ 80,873
(1) On July 8, 2014, NeoGenomics acquired the equity interests of Path Logic for $6.0 MM in an all cash transaction.
(2) On August 20, 2014, NeoGenomics completed the sale of 8.05 million shares of common stock at $4.60/share, which resulted in net
proceeds of $34.4 million after deducting the underwriters’ commissions and offering expenses.
20
21. Recent Share Price (3/12/15): $ 4.73
Common Shares Outstanding: 60.3 M
Fully Diluted Shares: 64.9 M
Avg. Daily Trading Volume (3 Mos.): 232,473
Current Market Cap: $285.2 M
Less Net Debt: (24.6)M
Enterprise Valuation: $260.6 M
Key Financial Information
21
22. NeoGenomics Summary
• Emerging leader in fastest-growing segment of lab testing industry
• Robust competitive advantages and product portfolio
• Strong Management Team with outstanding industry experience
• Accelerating profitability driven by growth and operating leverage
• Fragmented industry undergoing consolidation likely to present
additional strategic opportunities
• Recent Guidance(1): FY 2015
Revenue ($, MMs) $103 - 108
(1) Guidance incorporates an estimated $6-8 million reduction in revenue from the pricing of the new FISH CPT Codes by all Payers.
22